At Silence, our vision is to transform peoples’ lives around the world by silencing diseases through our
precision engineered medicines and driving positive change for the communities around us. As pioneers in the design
and development of siRNAs (short interfering RNAs), we are advancing a new generation of medicines to potentially
address the needs of patients who have limited or inadequate treatment options. Our investigational product
candidates are designed to harness the body's natural mechanism of RNA interference (RNAi) to precisely target and
silence disease-associated genes.
Silence conducts clinical trials to ensure that our investigational product candidates are safe and effective, which
supports approval of the treatment by regulatory authorities and ultimately enables patients to access approved,
safe and effective treatments.
At this time, Silence does not offer an expanded access program for its investigational products and these can only
be accessed by participation in a clinical trial. If in the future Silence decides to offer an expanded access
program, Silence will update its policy accordingly. If you are a patient who is interested in accessing one of our
investigational products by participating in a clinical trial, please consult with your physician. Anyone who wishes
to learn more about Silence’s investigational products or this policy can contact Silence by emailing [email protected]. More information on
Silence’s clinical trials can be found at www.clinicaltrials.gov.